IgG replacement therapy, no size fits all

Clinical Immunology

Volumn 139, Issue 2, 2011, Pages 107-109

  Bonilla, Francisco A ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G;

AREA UNDER THE CURVE; BIOAVAILABILITY; BIOEQUIVALENCE; DRUG EFFICACY; EDITORIAL; HUMAN; IMMUNOTHERAPY; INDIVIDUALITY; PRIORITY JOURNAL;

AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BRAZIL; EUROPE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOLOGIC FACTORS; INFUSIONS, SUBCUTANEOUS; PHARMACOKINETICS; THERAPEUTIC EQUIVALENCY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 79954611101     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2011.02.020     Document Type: Editorial

References (7)

1. Berger M., Rojavin M., Kiessling P., Zenker O. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiency. Clin. Immunol. 2011, 139:133-141.
2. Baumann A. Early development of therapeutic biologics-pharmacokinetics. Curr. Drug Metab. 2006, 7:15-21.
3. Bonilla F.A. Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes. Immunol. Allergy Clin. North Am. 2008, 28:803-819. ix.
4. Orange J.S., Hossny E.M., Weiler C.R., Ballow M., Berger M., Bonilla F.A., Buckley R., Chinen J., El-Gamal Y., Mazer B.D., Nelson R.P., Patel D.D., Secord E., Sorensen R.U., Wasserman R.L., Cunningham-Rundles C. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy. Asthma and immunology. J. Allergy Clin. Immunol. 2006, 117:S525-S553.
5. Berger M., Murphy E., Riley P., Bergman G.E. Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G. S. Med J 2010, 103:856-863.
6. J.S. Orange, W.J. Grossman, R.J. Navickis, and M.M. Wilkes, Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clin Immunol 137 21-30.
7. Bonagura V.R., Marchlewski R., Cox A., Rosenthal D.W. Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. J. Allergy Clin. Immunol. 2008, 122:210-212.